Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Quizartinib advances overall survival in acute myeloid leukaemia patients

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

ASCO 2022: Breast cancer highlights

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody